Trial Outcomes & Findings for Esophageal Cooling in Radiofrequency Cardiac Ablation (NCT NCT03481023)

NCT ID: NCT03481023

Last Updated: 2024-02-28

Results Overview

Esophageal mucosal damage as assessed by endoscopic evaluation using Zagar's Modified Endoscopic Classification Scheme. Higher scores on this scale indicate a worse outcome. The grading system is as follows: Grade 0: Normal Examination; Grade 1: Edema and Hypermia of the Mucosa; Grade 2a: Superficial ulceration, erosions, friability, blisters, exudates, hemorrhages, whitish membranes; Grade 2b: Grade 2a pluse deep discrete or circumferential ulcerations; Grade 3a: Small scattered areas of multiple ulceration and areas of necrosis with brown-black or greyish discoloration; Grade 3b: Extensive necrosis. For this grading scale we used the following scoring: 0=0 1=1 2a=2 2b=3 3a=4 3b=5

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

6 participants

Primary outcome timeframe

The post-intervention outcome measure was performed within 1 day after Pulmonary Vein Isolation.

Results posted on

2024-02-28

Participant Flow

No washout or run-in occurred after participants were enrolled in the study. Of the 7 patients that were recruited, one subject was excluded from the research study, because his BMI was outside of the study inclusion/exclusion criteria.

Participant milestones

Participant milestones
Measure
Esophageal Thermal Regulation Device
EnsoETM: Use of esophageal thermal regulation device during radiofrequency ablation.
LET Monitoring
Conventional Care: Use of luminal esophageal temperature monitoring during radiofrequency ablation procedure.
Overall Study
STARTED
3
3
Overall Study
COMPLETED
3
3
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Race and Ethnicity were not collected from any participant.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Esophageal Thermal Regulation Device
n=3 Participants
EnsoETM: Use of esophageal thermal regulation device during radiofrequency ablation.
LET Monitoring
n=3 Participants
Conventional Care: Use of luminal esophageal temperature monitoring during radiofrequency ablation procedure.
Total
n=6 Participants
Total of all reporting groups
Age, Categorical
<=18 years
0 Participants
n=3 Participants
0 Participants
n=3 Participants
0 Participants
n=6 Participants
Age, Categorical
Between 18 and 65 years
1 Participants
n=3 Participants
2 Participants
n=3 Participants
3 Participants
n=6 Participants
Age, Categorical
>=65 years
2 Participants
n=3 Participants
1 Participants
n=3 Participants
3 Participants
n=6 Participants
Age, Continuous
64.7 years
n=3 Participants
61.3 years
n=3 Participants
63 years
n=6 Participants
Sex: Female, Male
Female
0 Participants
n=3 Participants
1 Participants
n=3 Participants
1 Participants
n=6 Participants
Sex: Female, Male
Male
3 Participants
n=3 Participants
2 Participants
n=3 Participants
5 Participants
n=6 Participants
Race and Ethnicity Not Collected
0 Participants
Race and Ethnicity were not collected from any participant.
Region of Enrollment
United States
3 Participants
n=3 Participants
3 Participants
n=3 Participants
6 Participants
n=6 Participants

PRIMARY outcome

Timeframe: The post-intervention outcome measure was performed within 1 day after Pulmonary Vein Isolation.

Esophageal mucosal damage as assessed by endoscopic evaluation using Zagar's Modified Endoscopic Classification Scheme. Higher scores on this scale indicate a worse outcome. The grading system is as follows: Grade 0: Normal Examination; Grade 1: Edema and Hypermia of the Mucosa; Grade 2a: Superficial ulceration, erosions, friability, blisters, exudates, hemorrhages, whitish membranes; Grade 2b: Grade 2a pluse deep discrete or circumferential ulcerations; Grade 3a: Small scattered areas of multiple ulceration and areas of necrosis with brown-black or greyish discoloration; Grade 3b: Extensive necrosis. For this grading scale we used the following scoring: 0=0 1=1 2a=2 2b=3 3a=4 3b=5

Outcome measures

Outcome measures
Measure
Esophageal Thermal Regulation Device
n=3 Participants
EnsoETM: Use of esophageal thermal regulation device during radiofrequency ablation.
LET Monitoring
n=3 Participants
Conventional Care: Use of luminal esophageal temperature monitoring during radiofrequency ablation procedure.
Esophageal Mucosal Damage
1 score on a scale
Interval 0.0 to 2.0
1.33333 score on a scale
Interval 0.0 to 2.0

SECONDARY outcome

Timeframe: 3 months

Outcome measures

Outcome measures
Measure
Esophageal Thermal Regulation Device
n=3 Participants
EnsoETM: Use of esophageal thermal regulation device during radiofrequency ablation.
LET Monitoring
n=3 Participants
Conventional Care: Use of luminal esophageal temperature monitoring during radiofrequency ablation procedure.
Number and Percentage of Participants With Treatment-Emergent Adverse Events [Safety and Adverse Events]
0 Participants
0 Participants

SECONDARY outcome

Timeframe: 1 day

Altered submucosal tissue architecture as assessed by endoscopic ultrasound (EUS)

Outcome measures

Outcome measures
Measure
Esophageal Thermal Regulation Device
n=3 Participants
EnsoETM: Use of esophageal thermal regulation device during radiofrequency ablation.
LET Monitoring
n=3 Participants
Conventional Care: Use of luminal esophageal temperature monitoring during radiofrequency ablation procedure.
Presence of Esophageal Submucosal Damage, Indicated by Number of Ulcers as Assessed by Endoscopic Ultrasound (EUS)
.33 Ulcers
Interval 0.0 to 1.0
1 Ulcers
Interval 0.0 to 2.0

Adverse Events

Esophageal Thermal Regulation Device

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

LET Monitoring

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr. Brad Suprenant

Riverside Medical Center

Phone: (815) 939-9400

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place